Antisense & RNAi Therapeutics Market By Technology, Route of Administration, Application and Region – Global Industry Analysis, Market Share, Trends, Size, and Forecasts to 2020 – 2027.

Global Antisense and RNAi Therapeutics Market was valued at US$ X1.2X Bn in 2019 and is expected to reach US$ XX Bn by 2027, at a CAGR of X7.XX% during the forecast period of 2020 to 2027.

 Global Antisense and RNAi Therapeutics Market To know about the Research Methodology:- Request Free Sample Report

Global Antisense and RNAi Therapeutics Market: Overview 

In past years, pharmaceutical companies were motivated about the prospective of RNA interference (RNAi). But later, financial volatility and subsequent suspensions by pharmaceutical companies have articulated that the RNAi therapeutics market was finished. Yet, advances in nanomedicine helped the vast potential of RNAi therapeutics to flourish. Antisense technology offers the prospect to influence gene expression and this is being considered as an effective treatment for various diseases. Based on this factor, a great number of gene silencing drugs are in the development process. The report study has analyzed the revenue impact of a covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and the same is reflected in our analysis. The global antisense and RNAi therapeutics market have gathered substantial attention in recent years, due to its perspective to treat any sort of chronic diseases such as tuberculosis, diabetes, cancer, AIDS, as well as certain cardiovascular problems.  This prospect is being cashed on by the many companies in this industry and is investing in R&D. Just to emerge as being in the clinical research division, the RNA-based therapeutics are likely to be explored as a most efficient treatment choice for the disorders, which are very difficult to treat. The market is expected to grow at CAGR XX.XX % over the forecast period, the number of companies are into the development of molecules focused on antisense technology. However, there are many challenges associated with the emerging antisense technology and RNAi. One of the noticeable issues is the drug delivery to the proposed portion. Drug delivery to the nervous tissues is one of the problems as the drug has to pass the blood-brain barrier. Major players in the industry are coming up with solutions to overcome these challenges. The other challenge is the toxic effects caused by the use of this technology. Determining the right dosage and path for drug delivery of an antisense molecule is one of the most crucial processes to ensure safe administration. While overcoming this as much as possible and implementing it, companies have encountered multiple rejections from the regulatory bodies. For instance, FDA has refused, an antisense molecule to treat familial chylomicronemia syndrome by the renowned U.S. organization Akcea’s Waylivra. Such events would push companies to develop better paths, efficient delivery solutions, and effective compositions.

Global Antisense and RNAi Therapeutics Market: Segmentation

The global antisense and RNAi therapeutics market is classified into technology, application, and route of administration. In terms of technology, the global antisense and RNAi therapeutics market is bifurcated into RNA interference and antisense RNA. The segment of RNA interference is further sub-divided into miRNA and siRNA. In terms of application, the global antisense and RNAi therapeutics market are categorized into cardiovascular, oncology, renal diseases, respiratory disorder, genetic disorders, neurodegenerative disorder, infectious diseases, and others. In terms of route of administration, the global antisense and RNAi therapeutics market is sub-segmented into intravenous injections, pulmonary delivery, intraperitoneal injections, intradermal Injections, topical delivery, and other delivery methods.

Global Antisense and RNAi Therapeutics Market: Growth Factors

In RNAi therapeutics, more influential product focus vs. platform technologies and virtual drug expansion models that enable several companies to minimize the R&D costs, are expected to attract investors and supplement the growth of the market. Instead, major issues in drug delivery, as well as high failure rates, are some of the biggest barriers for companies working in this particular field. Despite the limitations, the players in the pharmaceutical sector are interested and focused on the commercialization of these therapies, hence the antisense and RNAi therapeutics market have the chances to grow substantially with the CAGR of XX.XX % and expected to reach US$ XX.XX Mn by the end of the forecast period.

Global Antisense and RNAi Therapeutics Market: Regional Analysis

North America has experienced being the most lucrative market in recent times and has contributed a substantial share in the Global Antisense and RNAi Therapeutics Market. Multiple clinical trials have shown favourable results and are even progressing through the development stages. Supposing such trials expected to show positive results, the North American market can be expected to witness exponential growth during the forecast period. Furthermore, in the U.S. several biotechnology companies have made considerably high investments for RNAi therapeutic development and a number of RNAi therapeutics are in the final stage of development phases. In North America, clinical laboratories are likely to contribute significant revenue generation via platform and product licensing. Supportive government regulation and provision to increase the number of clinical trials therein encourages the method of initiation for exploring antisense therapeutics. The forthcoming commercialization of several players are under R&D will help to boost the global antisense and RNAi therapeutics market in North America in the forecast period. The increasing government expenditure toward R&D, as well as different forms of siRNA delivery methods, is a strong side propelling the growth of the global antisense and RNAi therapeutics market in the Asia Pacific region. Still, this region is experiencing a moderate growth rate with a CAGR of XX.XX % during 2014-2018, but post commercialization of these therapies, prospects, and forthcoming opportunities in the Asia Pacific are likely to be more profitable, presenting a maximum development rate with the consistently growing CAGR of XX.XX % in the forecast period from 2020 to 2027.

Global Antisense and RNAi Therapeutics Market Insights and developments

In recent years there are many discoveries in the field of technologies with regard to the Global Antisense & RNAi Therapeutics Market, which in turn will help the industry to grow. Big pharmaceutical developers have entered into collaboration agreements or outsourcing deals with several smaller firms & new entrants in an effort to take advantage of the expected growth in revenue that this market can generate over the forecast period. For instance, the Agreement between AstraZeneca’s and Ionis pharmaceuticals is one of the big deals that are hugely investing & doing R&D into antisense technology. Since the discovery of RNAi, there are various ways of treatment of multiple diseases using RNAi, still, the market has picked up very little over the past decade due to the complexities in delivery methodologies associated with RNAi. But due to initiatives by key players and ongoing R&D have shown the chances of better growth. The rising need for the cure and prevention of diseases like cancer, AIDS and several diseases caused by mutating viruses is anticipated to impact the usage rate of oligonucleotide products. This field is rapidly expanding owing to the increasing number of clinical trials for oligonucleotide drugs. For instance, Ionis Pharmaceuticals has 2 approved molecules in the European Union and 1 in the U.S. along with 4 molecules in the pipeline. Many key players are putting efforts into developing novel delivery systems like nanocarriers, to encourage the in-vivo delivery of the oligonucleotides. To develop the bioavailability, the carrying capability of siRNA payload and the deliver high interface with the target cells are the key functions of Nanocarriers, for which they are recognized mostly. The development of newer nanotechnology-oriented methods has offered a high potential to the market to grow during the forecast period. Nanocarriers can reduce the toxicity of these oligonucleotides. There is a huge need for the latest and harmless delivery systems for cancer and other viral diseases, which is expected to supplement the market growth. Significant pipeline for cancer therapies by organizations and institutes such as Enzon Pharmaceuticals (Santaris Pharma), OncoGenex, University of Texas, Astrazeneca (Ionis Pharmaceuticals), Isarna Therapeutics and INSYS Therapeutics, Inc. have a huge contribution in driving the market. Detailed analysis of competition, new entrants, strategic alliances, mergers and acquisition in the Global Antisense & RNAi Therapeutics Market is covered in the report.  The report covers the market leaders and followers in the industry with the market dynamics by region. It will also help to understand the position of each player in the market by region, by segment.

Scope of the Global Antisense and RNAi Therapeutics Market: Inquire before buying

Global Antisense & RNAi Therapeutics Market Company Profiles –

The players operating in the Global Antisense & RNAi Therapeutics Market, analysed in the report are: • GSK, • Sanofi-Genzyme, • Alnylam Pharmaceuticals, • Marina Biosciences, • Benitec Biopharma, • Alnylam Pharmaceuticals, • Ionis Pharmaceuticals, • Akcea Therapeutics, • Quark Pharmaceuticals, • Gene Signal • Astellas Pharma Inc • Dicerna Pharmaceuticals • Tekmira Pharmaceuticals • Benitec Biopharma • Silence Therapeutics • Cenix BioScience • Sirnaomics • CureVac AG

Global Antisense and RNAi Therapeutics Market, by Technology

• RNA Interference o siRNA o miRNA • Antisense RNA

Global Antisense and RNAi Therapeutics Market, by Application

• Oncology • Cardiovascular Diseases (CVDs) • Respiratory Disorders • Renal Diseases • Neurodegenerative Disorders • Genetic Disorders • Infectious Diseases • Other

Global Antisense and RNAi Therapeutics Market, by Route of Administration

• Pulmonary Delivery • Intravenous Injections • Intra-dermal Injections • Intraperitoneal Injections • Topical Delivery • Other Delivery Methods

Global Antisense & RNAi Therapeutics Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Antisense & RNAi Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Antisense & RNAi Therapeutics Market Analysis and Forecast 6.1. Global Antisense & RNAi Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Antisense & RNAi Therapeutics Market Analysis and Forecast, by Technology 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology 7.4. Global Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Technology 7.5. Global Antisense & RNAi Therapeutics Market Analysis, by Technology 7.6. Global Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Technology 8. Global Antisense & RNAi Therapeutics Market Analysis and Forecast, by Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Antisense & RNAi Therapeutics Market Value Share Analysis, by Application 8.4. Global Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Application 8.5. Global Antisense & RNAi Therapeutics Market Analysis, by Application 8.6. Global Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Application 9. Global Antisense & RNAi Therapeutics Market Analysis and Forecast, by Route of Administration 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration 9.4. Global Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration 9.5. Global Antisense & RNAi Therapeutics Market Analysis, by Route of Administration 9.6. Global Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Route of Administration 10. Global Antisense & RNAi Therapeutics Market Analysis, by Region 10.1. Global Antisense & RNAi Therapeutics Market Value Share Analysis, by Region 10.2. Global Antisense & RNAi Therapeutics Market Size (US$ Bn) Forecast, by Region 10.3. Global Antisense & RNAi Therapeutics Market Attractiveness Analysis, by Region 11. North America Antisense & RNAi Therapeutics Market Analysis 11.1. Key Findings 11.2. North America Antisense & RNAi Therapeutics Market Overview 11.3. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology 11.4. North America Antisense & RNAi Therapeutics Market Forecast, by Technology 11.4.1. RNA Interference 11.4.1.1. siRNA 11.4.1.2. miRNA 11.4.2. Antisense RNA 11.5. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Application 11.6. North America Antisense & RNAi Therapeutics Market Forecast, by Application 11.6.1. Oncology 11.6.2. Cardiovascular Diseases (CVDs) 11.6.3. Respiratory Disorders 11.6.4. Renal Diseases 11.6.5. Neurodegenerative Disorders 11.6.6. Genetic Disorders 11.6.7. Infectious Diseases 11.6.8. Other 11.7. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration 11.8. North America Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 11.8.1. Pulmonary Delivery 11.8.2. Intravenous Injections 11.8.3. Intra-dermal Injections 11.8.4. Intraperitoneal Injections 11.8.5. Topical Delivery 11.8.6. Other Delivery Methods 11.9. North America Antisense & RNAi Therapeutics Market Value Share Analysis, by Country 11.10. North America Antisense & RNAi Therapeutics Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Antisense & RNAi Therapeutics Market Analysis, by Country 11.12. U.S. Antisense & RNAi Therapeutics Market Forecast, by Technology 11.12.1. RNA Interference 11.12.1.1. siRNA 11.12.1.2. miRNA 11.12.2. Antisense RNA 11.13. U.S. Antisense & RNAi Therapeutics Market Forecast, by Application 11.13.1. Oncology 11.13.2. Cardiovascular Diseases (CVDs) 11.13.3. Respiratory Disorders 11.13.4. Renal Diseases 11.13.5. Neurodegenerative Disorders 11.13.6. Genetic Disorders 11.13.7. Infectious Diseases 11.13.8. Other 11.14. U.S. Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 11.14.1. Pulmonary Delivery 11.14.2. Intravenous Injections 11.14.3. Intra-dermal Injections 11.14.4. Intraperitoneal Injections 11.14.5. Topical Delivery 11.14.6. Other Delivery Methods 11.15. Canada Antisense & RNAi Therapeutics Market Forecast, by Technology 11.15.1. RNA Interference 11.15.1.1. siRNA 11.15.1.2. miRNA 11.15.2. Antisense RNA 11.16. Steel Canada Antisense & RNAi Therapeutics Market Forecast, by Application 11.16.1. Oncology 11.16.2. Cardiovascular Diseases (CVDs) 11.16.3. Respiratory Disorders 11.16.4. Renal Diseases 11.16.5. Neurodegenerative Disorders 11.16.6. Genetic Disorders 11.16.7. Infectious Diseases 11.16.8. Other 11.17. Canada Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 11.17.1. Pulmonary Delivery 11.17.2. Intravenous Injections 11.17.3. Intra-dermal Injections 11.17.4. Intraperitoneal Injections 11.17.5. Topical Delivery 11.17.6. Other Delivery Methods 11.18. North America Antisense & RNAi Therapeutics Market Attractiveness Analysis 11.18.1. By Technology 11.18.2. By Application 11.18.3. By Route of Administration 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Antisense & RNAi Therapeutics Market Analysis 12.1. Key Findings 12.2. Europe Antisense & RNAi Therapeutics Market Overview 12.3. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology 12.4. Europe Antisense & RNAi Therapeutics Market Forecast, by Technology 12.4.1. RNA Interference 12.4.1.1. siRNA 12.4.1.2. miRNA 12.4.2. Antisense RNA 12.5. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Application 12.6. Europe Antisense & RNAi Therapeutics Market Forecast, by Application 12.6.1. Oncology 12.6.2. Cardiovascular Diseases (CVDs) 12.6.3. Respiratory Disorders 12.6.4. Renal Diseases 12.6.5. Neurodegenerative Disorders 12.6.6. Genetic Disorders 12.6.7. Infectious Diseases 12.6.8. Other 12.7. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration 12.8. Europe Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 12.8.1. Pulmonary Delivery 12.8.2. Intravenous Injections 12.8.3. Intra-dermal Injections 12.8.4. Intraperitoneal Injections 12.8.5. Topical Delivery 12.8.6. Other Delivery Methods 12.9. Europe Antisense & RNAi Therapeutics Market Value Share Analysis, by Country 12.10. Europe Antisense & RNAi Therapeutics Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Antisense & RNAi Therapeutics Market Analysis, by Country 12.12. Germany Antisense & RNAi Therapeutics Market Forecast, by Technology 12.12.1. RNA Interference 12.12.1.1. siRNA 12.12.1.2. miRNA 12.12.2. Antisense RNA 12.13. Germany Antisense & RNAi Therapeutics Market Forecast, by Application 12.13.1. Oncology 12.13.2. Cardiovascular Diseases (CVDs) 12.13.3. Respiratory Disorders 12.13.4. Renal Diseases 12.13.5. Neurodegenerative Disorders 12.13.6. Genetic Disorders 12.13.7. Infectious Diseases 12.13.8. Other 12.14. Germany Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 12.14.1. Pulmonary Delivery 12.14.2. Intravenous Injections 12.14.3. Intra-dermal Injections 12.14.4. Intraperitoneal Injections 12.14.5. Topical Delivery 12.14.6. Other Delivery Methods 12.15. U.K. Antisense & RNAi Therapeutics Market Forecast, by Technology 12.15.1. RNA Interference 12.15.1.1. siRNA 12.15.1.2. miRNA 12.15.2. Antisense RNA 12.16. U.K. Antisense & RNAi Therapeutics Market Forecast, by Application 12.16.1. Oncology 12.16.2. Cardiovascular Diseases (CVDs) 12.16.3. Respiratory Disorders 12.16.4. Renal Diseases 12.16.5. Neurodegenerative Disorders 12.16.6. Genetic Disorders 12.16.7. Infectious Diseases 12.16.8. Other 12.17. U.K. Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 12.17.1. Pulmonary Delivery 12.17.2. Intravenous Injections 12.17.3. Intra-dermal Injections 12.17.4. Intraperitoneal Injections 12.17.5. Topical Delivery 12.17.6. Other Delivery Methods 12.18. France Antisense & RNAi Therapeutics Market Forecast, by Technology 12.18.1. RNA Interference 12.18.1.1. siRNA 12.18.1.2. miRNA 12.18.2. Antisense RNA 12.19. France Antisense & RNAi Therapeutics Market Forecast, by Application 12.19.1. Oncology 12.19.2. Cardiovascular Diseases (CVDs) 12.19.3. Respiratory Disorders 12.19.4. Renal Diseases 12.19.5. Neurodegenerative Disorders 12.19.6. Genetic Disorders 12.19.7. Infectious Diseases 12.19.8. Other 12.20. France Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 12.20.1. Pulmonary Delivery 12.20.2. Intravenous Injections 12.20.3. Intra-dermal Injections 12.20.4. Intraperitoneal Injections 12.20.5. Topical Delivery 12.20.6. Other Delivery Methods 12.21. Italy Antisense & RNAi Therapeutics Market Forecast, by Technology 12.21.1. RNA Interference 12.21.1.1. siRNA 12.21.1.2. miRNA 12.21.2. Antisense RNA 12.22. Italy Antisense & RNAi Therapeutics Market Forecast, by Application 12.22.1. Oncology 12.22.2. Cardiovascular Diseases (CVDs) 12.22.3. Respiratory Disorders 12.22.4. Renal Diseases 12.22.5. Neurodegenerative Disorders 12.22.6. Genetic Disorders 12.22.7. Infectious Diseases 12.22.8. Other 12.23. Italy Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 12.23.1. Pulmonary Delivery 12.23.2. Intravenous Injections 12.23.3. Intra-dermal Injections 12.23.4. Intraperitoneal Injections 12.23.5. Topical Delivery 12.23.6. Other Delivery Methods 12.24. Spain Antisense & RNAi Therapeutics Market Forecast, by Technology 12.24.1. RNA Interference 12.24.1.1. siRNA 12.24.1.2. miRNA 12.24.2. Antisense RNA 12.25. Spain Antisense & RNAi Therapeutics Market Forecast, by Application 12.25.1. Oncology 12.25.2. Cardiovascular Diseases (CVDs) 12.25.3. Respiratory Disorders 12.25.4. Renal Diseases 12.25.5. Neurodegenerative Disorders 12.25.6. Genetic Disorders 12.25.7. Infectious Diseases 12.25.8. Other 12.26. Spain Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 12.26.1. Pulmonary Delivery 12.26.2. Intravenous Injections 12.26.3. Intra-dermal Injections 12.26.4. Intraperitoneal Injections 12.26.5. Topical Delivery 12.26.6. Other Delivery Methods 12.27. Rest of Europe Antisense & RNAi Therapeutics Market Forecast, by Technology 12.27.1. RNA Interference 12.27.1.1. siRNA 12.27.1.2. miRNA 12.27.2. Antisense RNA 12.28. Rest of Europe Antisense & RNAi Therapeutics Market Forecast, by Application 12.28.1. Oncology 12.28.2. Cardiovascular Diseases (CVDs) 12.28.3. Respiratory Disorders 12.28.4. Renal Diseases 12.28.5. Neurodegenerative Disorders 12.28.6. Genetic Disorders 12.28.7. Infectious Diseases 12.28.8. Other 12.29. Rest Of Europe Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 12.29.1. Pulmonary Delivery 12.29.2. Intravenous Injections 12.29.3. Intra-dermal Injections 12.29.4. Intraperitoneal Injections 12.29.5. Topical Delivery 12.29.6. Other Delivery Methods 12.30. Europe Antisense & RNAi Therapeutics Market Attractiveness Analysis 12.30.1. By Technology 12.30.2. By Application 12.30.3. By Route of Administration 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Antisense & RNAi Therapeutics Market Analysis 13.1. Key Findings 13.2. Asia Pacific Antisense & RNAi Therapeutics Market Overview 13.3. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology 13.4. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Technology 13.4.1. RNA Interference 13.4.1.1. siRNA 13.4.1.2. miRNA 13.4.2. Antisense RNA 13.5. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Application 13.6. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Application 13.6.1. Oncology 13.6.2. Cardiovascular Diseases (CVDs) 13.6.3. Respiratory Disorders 13.6.4. Renal Diseases 13.6.5. Neurodegenerative Disorders 13.6.6. Genetic Disorders 13.6.7. Infectious Diseases 13.6.8. Other 13.7. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration 13.8. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 13.8.1. Pulmonary Delivery 13.8.2. Intravenous Injections 13.8.3. Intra-dermal Injections 13.8.4. Intraperitoneal Injections 13.8.5. Topical Delivery 13.8.6. Other Delivery Methods 13.9. Asia Pacific Antisense & RNAi Therapeutics Market Value Share Analysis, by Country 13.10. Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Antisense & RNAi Therapeutics Market Analysis, by Country 13.12. China Antisense & RNAi Therapeutics Market Forecast, by Technology 13.12.1. RNA Interference 13.12.1.1. siRNA 13.12.1.2. miRNA 13.12.2. Antisense RNA 13.13. China Antisense & RNAi Therapeutics Market Forecast, by Application 13.13.1. Oncology 13.13.2. Cardiovascular Diseases (CVDs) 13.13.3. Respiratory Disorders 13.13.4. Renal Diseases 13.13.5. Neurodegenerative Disorders 13.13.6. Genetic Disorders 13.13.7. Infectious Diseases 13.13.8. Other 13.14. China Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 13.14.1. Pulmonary Delivery 13.14.2. Intravenous Injections 13.14.3. Intra-dermal Injections 13.14.4. Intraperitoneal Injections 13.14.5. Topical Delivery 13.14.6. Other Delivery Methods 13.15. India Antisense & RNAi Therapeutics Market Forecast, by Technology 13.15.1. RNA Interference 13.15.1.1. siRNA 13.15.1.2. miRNA 13.15.2. Antisense RNA 13.16. India Antisense & RNAi Therapeutics Market Forecast, by Application 13.16.1. Oncology 13.16.2. Cardiovascular Diseases (CVDs) 13.16.3. Respiratory Disorders 13.16.4. Renal Diseases 13.16.5. Neurodegenerative Disorders 13.16.6. Genetic Disorders 13.16.7. Infectious Diseases 13.16.8. Other 13.17. India Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 13.17.1. Pulmonary Delivery 13.17.2. Intravenous Injections 13.17.3. Intra-dermal Injections 13.17.4. Intraperitoneal Injections 13.17.5. Topical Delivery 13.17.6. Other Delivery Methods 13.18. Japan Antisense & RNAi Therapeutics Market Forecast, by Technology 13.18.1. RNA Interference 13.18.1.1. siRNA 13.18.1.2. miRNA 13.18.2. Antisense RNA 13.19. Japan Antisense & RNAi Therapeutics Market Forecast, by Application 13.19.1. Oncology 13.19.2. Cardiovascular Diseases (CVDs) 13.19.3. Respiratory Disorders 13.19.4. Renal Diseases 13.19.5. Neurodegenerative Disorders 13.19.6. Genetic Disorders 13.19.7. Infectious Diseases 13.19.8. Other 13.20. Japan Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 13.20.1. Pulmonary Delivery 13.20.2. Intravenous Injections 13.20.3. Intra-dermal Injections 13.20.4. Intraperitoneal Injections 13.20.5. Topical Delivery 13.20.6. Other Delivery Methods 13.21. ASEAN Antisense & RNAi Therapeutics Market Forecast, by Technology 13.21.1. RNA Interference 13.21.1.1. siRNA 13.21.1.2. miRNA 13.21.2. Antisense RNA 13.22. ASEAN Antisense & RNAi Therapeutics Market Forecast, by Application 13.22.1. Oncology 13.22.2. Cardiovascular Diseases (CVDs) 13.22.3. Respiratory Disorders 13.22.4. Renal Diseases 13.22.5. Neurodegenerative Disorders 13.22.6. Genetic Disorders 13.22.7. Infectious Diseases 13.22.8. Other 13.23. ASEAN Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 13.23.1. Pulmonary Delivery 13.23.2. Intravenous Injections 13.23.3. Intra-dermal Injections 13.23.4. Intraperitoneal Injections 13.23.5. Topical Delivery 13.23.6. Other Delivery Methods 13.24. Rest of Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Technology 13.24.1. RNA Interference 13.24.1.1. siRNA 13.24.1.2. miRNA 13.24.2. Antisense RNA 13.25. Rest of Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Application 13.25.1. Oncology 13.25.2. Cardiovascular Diseases (CVDs) 13.25.3. Respiratory Disorders 13.25.4. Renal Diseases 13.25.5. Neurodegenerative Disorders 13.25.6. Genetic Disorders 13.25.7. Infectious Diseases 13.25.8. Other 13.26. Rest of Asia Pacific Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 13.26.1. Pulmonary Delivery 13.26.2. Intravenous Injections 13.26.3. Intra-dermal Injections 13.26.4. Intraperitoneal Injections 13.26.5. Topical Delivery 13.26.6. Other Delivery Methods 13.27. Asia Pacific Antisense & RNAi Therapeutics Market Attractiveness Analysis 13.27.1. By Technology 13.27.2. By Application 13.27.3. By Route of Administration 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Antisense & RNAi Therapeutics Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Antisense & RNAi Therapeutics Market Overview 14.3. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology 14.4. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Technology 14.4.1. RNA Interference 14.4.1.1. siRNA 14.4.1.2. miRNA 14.4.2. Antisense RNA 14.5. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Application 14.6. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Application 14.6.1. Oncology 14.6.2. Cardiovascular Diseases (CVDs) 14.6.3. Respiratory Disorders 14.6.4. Renal Diseases 14.6.5. Neurodegenerative Disorders 14.6.6. Genetic Disorders 14.6.7. Infectious Diseases 14.6.8. Other 14.7. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration 14.8. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 14.8.1. Pulmonary Delivery 14.8.2. Intravenous Injections 14.8.3. Intra-dermal Injections 14.8.4. Intraperitoneal Injections 14.8.5. Topical Delivery 14.8.6. Other Delivery Methods 14.9. Middle East & Africa Antisense & RNAi Therapeutics Market Value Share Analysis, by Country 14.10. Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Antisense & RNAi Therapeutics Market Analysis, by Country 14.12. GCC Antisense & RNAi Therapeutics Market Forecast, by Technology 14.12.1. RNA Interference 14.12.1.1. siRNA 14.12.1.2. miRNA 14.12.2. Antisense RNA 14.13. GCC Antisense & RNAi Therapeutics Market Forecast, by Application 14.13.1. Oncology 14.13.2. Cardiovascular Diseases (CVDs) 14.13.3. Respiratory Disorders 14.13.4. Renal Diseases 14.13.5. Neurodegenerative Disorders 14.13.6. Genetic Disorders 14.13.7. Infectious Diseases 14.13.8. Other 14.14. GCC Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 14.14.1. Pulmonary Delivery 14.14.2. Intravenous Injections 14.14.3. Intra-dermal Injections 14.14.4. Intraperitoneal Injections 14.14.5. Topical Delivery 14.14.6. Other Delivery Methods 14.15. South Africa Antisense & RNAi Therapeutics Market Forecast, by Technology 14.15.1. RNA Interference 14.15.1.1. siRNA 14.15.1.2. miRNA 14.15.2. Antisense RNA 14.16. South Africa Antisense & RNAi Therapeutics Market Forecast, by Application 14.16.1. Oncology 14.16.2. Cardiovascular Diseases (CVDs) 14.16.3. Respiratory Disorders 14.16.4. Renal Diseases 14.16.5. Neurodegenerative Disorders 14.16.6. Genetic Disorders 14.16.7. Infectious Diseases 14.16.8. Other 14.17. South Africa Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 14.17.1. Pulmonary Delivery 14.17.2. Intravenous Injections 14.17.3. Intra-dermal Injections 14.17.4. Intraperitoneal Injections 14.17.5. Topical Delivery 14.17.6. Other Delivery Methods 14.18. Rest of Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Technology 14.18.1. RNA Interference 14.18.1.1. siRNA 14.18.1.2. miRNA 14.18.2. Antisense RNA 14.19. Rest of Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Application 14.19.1. Oncology 14.19.2. Cardiovascular Diseases (CVDs) 14.19.3. Respiratory Disorders 14.19.4. Renal Diseases 14.19.5. Neurodegenerative Disorders 14.19.6. Genetic Disorders 14.19.7. Infectious Diseases 14.19.8. Other 14.20. Rest of Middle East & Africa Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 14.20.1. Pulmonary Delivery 14.20.2. Intravenous Injections 14.20.3. Intra-dermal Injections 14.20.4. Intraperitoneal Injections 14.20.5. Topical Delivery 14.20.6. Other Delivery Methods 14.21. Middle East & Africa Antisense & RNAi Therapeutics Market Attractiveness Analysis 14.21.1. By Technology 14.21.2. By Application 14.21.3. By Route of Administration 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Antisense & RNAi Therapeutics Market Analysis 15.1. Key Findings 15.2. South America Antisense & RNAi Therapeutics Market Overview 15.3. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Technology 15.4. South America Antisense & RNAi Therapeutics Market Forecast, by Technology 15.4.1. RNA Interference 15.4.1.1. siRNA 15.4.1.2. miRNA 15.4.2. Antisense RNA 15.5. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Application 15.6. South America Antisense & RNAi Therapeutics Market Forecast, by Application 15.6.1. Oncology 15.6.2. Cardiovascular Diseases (CVDs) 15.6.3. Respiratory Disorders 15.6.4. Renal Diseases 15.6.5. Neurodegenerative Disorders 15.6.6. Genetic Disorders 15.6.7. Infectious Diseases 15.6.8. Other 15.7. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Route of Administration 15.8. South America Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 15.8.1. Pulmonary Delivery 15.8.2. Intravenous Injections 15.8.3. Intra-dermal Injections 15.8.4. Intraperitoneal Injections 15.8.5. Topical Delivery 15.8.6. Other Delivery Methods 15.9. South America Antisense & RNAi Therapeutics Market Value Share Analysis, by Country 15.10. South America Antisense & RNAi Therapeutics Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Antisense & RNAi Therapeutics Market Analysis, by Country 15.12. Brazil Antisense & RNAi Therapeutics Market Forecast, by Technology 15.12.1. RNA Interference 15.12.1.1. siRNA 15.12.1.2. miRNA 15.12.2. Antisense RNA 15.13. Brazil Antisense & RNAi Therapeutics Market Forecast, by Application 15.13.1. Oncology 15.13.2. Cardiovascular Diseases (CVDs) 15.13.3. Respiratory Disorders 15.13.4. Renal Diseases 15.13.5. Neurodegenerative Disorders 15.13.6. Genetic Disorders 15.13.7. Infectious Diseases 15.13.8. Other 15.14. Brazil Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 15.14.1. Pulmonary Delivery 15.14.2. Intravenous Injections 15.14.3. Intra-dermal Injections 15.14.4. Intraperitoneal Injections 15.14.5. Topical Delivery 15.14.6. Other Delivery Methods 15.15. Mexico Antisense & RNAi Therapeutics Market Forecast, by Technology 15.15.1. RNA Interference 15.15.1.1. siRNA 15.15.1.2. miRNA 15.15.2. Antisense RNA 15.16. Mexico Antisense & RNAi Therapeutics Market Forecast, by Application 15.16.1. Oncology 15.16.2. Cardiovascular Diseases (CVDs) 15.16.3. Respiratory Disorders 15.16.4. Renal Diseases 15.16.5. Neurodegenerative Disorders 15.16.6. Genetic Disorders 15.16.7. Infectious Diseases 15.16.8. Other 15.17. Mexico Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 15.17.1. Pulmonary Delivery 15.17.2. Intravenous Injections 15.17.3. Intra-dermal Injections 15.17.4. Intraperitoneal Injections 15.17.5. Topical Delivery 15.17.6. Other Delivery Methods 15.18. Rest of South America Antisense & RNAi Therapeutics Market Forecast, by Technology 15.18.1. RNA Interference 15.18.1.1. siRNA 15.18.1.2. miRNA 15.18.2. Antisense RNA 15.19. Rest of South America Antisense & RNAi Therapeutics Market Forecast, by Application 15.19.1. Oncology 15.19.2. Cardiovascular Diseases (CVDs) 15.19.3. Respiratory Disorders 15.19.4. Renal Diseases 15.19.5. Neurodegenerative Disorders 15.19.6. Genetic Disorders 15.19.7. Infectious Diseases 15.19.8. Other 15.20. Rest of South America Antisense & RNAi Therapeutics Market Forecast, by Route of Administration 15.20.1. Pulmonary Delivery 15.20.2. Intravenous Injections 15.20.3. Intra-dermal Injections 15.20.4. Intraperitoneal Injections 15.20.5. Topical Delivery 15.20.6. Other Delivery Methods 15.21. South America Antisense & RNAi Therapeutics Market Attractiveness Analysis 15.21.1. By Technology 15.21.2. By Application 15.21.3. By Route of Administration 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Alnylam Pharmaceuticals, 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. GSK, 16.3.3. Sanofi-Genzyme, 16.3.4. Marina Biosciences, 16.3.5. Benitec Biopharma, 16.3.6. Alnylam Pharmaceuticals, 16.3.7. Ionis Pharmaceuticals, 16.3.8. Akcea Therapeutics, 16.3.9. Quark Pharmaceuticals, 16.3.10. Gene Signal 16.3.11. Astellas Pharma Inc 16.3.12. Dicerna Pharmaceuticals 16.3.13. Tekmira Pharmaceuticals 16.3.14. Benitec Biopharma 16.3.15. Silence Therapeutics 16.3.16. Cenix BioScience 16.3.17. Sirnaomics 16.3.18. CureVac AG 17. Primary Key Insights

About This Report

Report ID 46233
Category Material & Chemical
Published Date Jan 2020
Updated Date
Contact Us